delivered impressive Q3FY26 results with 31.3% revenue growth to ₹1,612.2 million, led by API exports surge of 109.8%. EBITDA increased 34.6% to ₹323.3 million with expanding margins. The company achieved key regulatory milestones including first-in-India CDSCO approval for Suvorexant trials and launched Magnesium L-Threonate. Nine-month performance showed 18% revenue growth with profit rising 36.4% to ₹386.2 million, demonstrating sustained operational momentum across all business segments. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.